Dermatitis Clinical Trials

201 recruitingLast updated: May 21, 2026

There are 201 actively recruiting dermatitis clinical trials across 55 countries. Studies span Not Applicable, Phase 2, Phase 1, Phase 3, Phase 4. Top locations include New York, New York, United States, Birmingham, Alabama, United States, Los Angeles, California, United States. Updated daily from ClinicalTrials.gov.


Dermatitis Trials at a Glance

201 actively recruiting trials for dermatitis are listed on ClinicalTrialsFinder across 6 cities in 55 countries. The largest study group is Not Applicable with 46 trials, with the heaviest enrollment activity in New York, Birmingham, and Los Angeles. Lead sponsors running dermatitis studies include Pfizer, Sanofi, and National Institute of Allergy and Infectious Diseases (NIAID).

Browse dermatitis trials by phase

About Dermatitis Clinical Trials

Looking for clinical trials for Dermatitis? There are currently 9 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Dermatitis trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Dermatitis clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 201 trials

Recruiting
Phase 1

Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis

Atopic DermatitisLupusHyper IgE Syndrome From STAT3 Mutation+2 more
National Institute of Allergy and Infectious Diseases (NIAID)20 enrolled1 locationNCT07262983
Recruiting

Natural History and Genetics of Food Allergy and Related Conditions

eosinophilic esophagitisAtopic DermatitisFood allergy+1 more
National Institute of Allergy and Infectious Diseases (NIAID)1,800 enrolled1 locationNCT02504853
Recruiting

French Prospective Observational Study in Patients Eligible for Systemic Therapy for Atopic Dermatitis (AD)

Atopic Dermatitis
Sanofi600 enrolled62 locationsNCT06837454
Recruiting
Phase 1

A Phase 1 Clinical Study Comparing GS101 and Dupixent® After Subcutaneous Injection

Atopic Dermatitis (AD)
Jiangsu Genscend Biopharmaceutical Co., Ltd294 enrolled1 locationNCT07411755
Recruiting

Mechanisms of Increased Disease Severity in AD Patients With the IL-4Ra R576 Polymorphism

Atopic Dermatitis
Boston Children's Hospital111 enrolled1 locationNCT04455906
Recruiting
Phase 2

A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis

DermatitisAtopic DermatitisEczema Atopic Dermatitis+5 more
Apollo Therapeutics Ltd280 enrolled85 locationsNCT07599813
Recruiting
Phase 2

A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis

Atopic Dermatitis
Kymera Therapeutics, Inc.200 enrolled67 locationsNCT07217015
Recruiting
Phase 2

A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis

Atopic Dermatitis
Apogee Therapeutics, Inc.350 enrolled48 locationsNCT07003425
Recruiting
Phase 3

A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis

Atopic Dermatitis
Organon and Co180 enrolled47 locationsNCT07265479
Recruiting
Phase 2

A Double-Blind, Randomized, Vehicle-Controlled Phase 2 Study to Assess the Efficacy and Safety of GX-03 in Adult Subjects With Moderate to Severe Atopic Dermatitis (Eczema)

Atopic DermatitisEczema Atopic DermatitisEczema
Turn Therapeutics110 enrolled1 locationNCT07355075
Recruiting

The Impact of Dupilumab Treatment on Anxiety and Depression Symptoms in Patients With Moderate-to-Severe Atopic Dermatitis

Atopic Dermatitis
Sanofi184 enrolled2 locationsNCT07467564
Recruiting

An Observational Study to Assess Real-World Use of Upadacitinib Tablets in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis in China

Atopic Dermatitis
AbbVie1,000 enrolled38 locationsNCT06421740
Recruiting
Phase 3

A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab

Atopic Dermatitis
AbbVie200 enrolled126 locationsNCT06389136
Recruiting
Phase 2

Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis

Atopic Dermatitis (AD)
Enveda Therapeutics60 enrolled20 locationsNCT07298395
Recruiting
Phase 2

A Long Term Extension Study to Evaluate the Safety and Efficacy of Afimkibart (RO7790121) in Participants With Atopic Dermatitis

Atopic Dermatitis
Hoffmann-La Roche120 enrolled14 locationsNCT07223697
Recruiting
Phase 2

A Dose-ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Atopic Dermatitis

Atopic Dermatitis
UCB Biopharma SRL160 enrolled57 locationsNCT07277660
Recruiting
Phase 3

A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor

Dermatitis Atopic
Sanofi636 enrolled147 locationsNCT06241118
Recruiting
Phase 2

A Study of JNJ-95597528 in Participants With Moderate to Severe Atopic Dermatitis

Dermatitis Atopic
Janssen Research & Development, LLC180 enrolled56 locationsNCT07230860
Recruiting
Not Applicable

Randomized, Blinded, Placebo-Controlled Evaluation of BioAmicus Complete

ConstipationAtopic DermatitisInfantile Colics+1 more
NovoNatum Ltd140 enrolled1 locationNCT07444008
Recruiting
Phase 1

A Study of SKB575 (HBM7575) Injection in Healthy Participants and Atopic Dermatitis Participants

Atopic Dermatitis
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.90 enrolled2 locationsNCT07488065